Literature DB >> 22673568

Systemic VHL gene functions and the VHL disease.

Hannah L Bader1, Tien Hsu.   

Abstract

The von Hippel-Lindau tumor suppressor gene (VHL) is best known as an E3 ubiquitin ligase that negatively regulates the hypoxia inducible factor (HIF). VHL mutations are the genetic defects underlying several human diseases including polycythemia, familial VHL tumor syndrome and sporadic renal cell carcinoma. VHL mutations can lead to cell-autonomous phenotypes in the tumor cells. However, non-tumor cell-autonomous functions of VHL have also been noted. VHL tumor-derived cytokines can promote inflammation and induce mobilization of endothelial progenitor cells. Up-regulation of HIF caused by VHL loss-of-function mutants, including heterozygotes, has been shown to increase the activities of hematopoietic stem cells, endothelial cells and myeloid cells. As such, systemic functions of VHL likely play important roles in the development of VHL disease.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22673568      PMCID: PMC3372859          DOI: 10.1016/j.febslet.2012.04.032

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  138 in total

Review 1.  The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing.

Authors:  William G Kaelin
Journal:  Biochem Biophys Res Commun       Date:  2005-08-30       Impact factor: 3.575

2.  HIF-1alpha expression regulates the bactericidal capacity of phagocytes.

Authors:  Carole Peyssonnaux; Vivekanand Datta; Thorsten Cramer; Andrew Doedens; Emmanuel A Theodorakis; Richard L Gallo; Nancy Hurtado-Ziola; Victor Nizet; Randall S Johnson
Journal:  J Clin Invest       Date:  2005-07       Impact factor: 14.808

3.  Edema is a precursor to central nervous system peritumoral cyst formation.

Authors:  Russell R Lonser; Alexander O Vortmeyer; John A Butman; Sven Glasker; Michael A Finn; Joshua M Ammerman; Marsha J Merrill; Nancy A Edwards; Zhengping Zhuang; Edward H Oldfield
Journal:  Ann Neurol       Date:  2005-09       Impact factor: 10.422

4.  Cellular and reticular variants of haemangioblastoma revisited: a clinicopathologic study of 88 cases.

Authors:  M Hasselblatt; A Jeibmann; J Gerss; C Behrens; B Rama; H Wassmann; W Paulus
Journal:  Neuropathol Appl Neurobiol       Date:  2005-12       Impact factor: 8.090

5.  Hypoxia inducible factor 1 alpha regulates T cell receptor signal transduction.

Authors:  Aaron K Neumann; Jaeseok Yang; Mangat P Biju; Suresh K Joseph; Randall S Johnson; Volker H Haase; Bruce D Freedman; Laurence A Turka
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-14       Impact factor: 11.205

Review 6.  Diabetes and insulin secretion: the ATP-sensitive K+ channel (K ATP) connection.

Authors:  Joseph C Koster; M Alan Permutt; Colin G Nichols
Journal:  Diabetes       Date:  2005-11       Impact factor: 9.461

7.  Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor.

Authors:  David Zagzag; Balaji Krishnamachary; Herman Yee; Hiroaki Okuyama; Luis Chiriboga; M Aktar Ali; Jonathan Melamed; Gregg L Semenza
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

8.  Hemangioblastomas share protein expression with embryonal hemangioblast progenitor cell.

Authors:  Sven Gläsker; Jie Li; John B Xia; Hiroaki Okamoto; Weifen Zeng; Russell R Lonser; Zhengping Zhuang; Edward H Oldfield; Alexander O Vortmeyer
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

9.  Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.

Authors:  Jiabin An; Matthew B Rettig
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

10.  Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.

Authors:  Rosamonde E Banks; Prasanna Tirukonda; Claire Taylor; Nick Hornigold; Dewi Astuti; Dena Cohen; Eamonn R Maher; Anthea J Stanley; Patricia Harnden; Adrian Joyce; Margaret Knowles; Peter J Selby
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

View more
  31 in total

1.  Clinical utility gene card for: von Hippel-Lindau (VHL).

Authors:  Jochen Decker; Christine Neuhaus; Fiona Macdonald; Hiltrud Brauch; Eamonn R Maher
Journal:  Eur J Hum Genet       Date:  2013-08-28       Impact factor: 4.246

Review 2.  Wnt Antagonists in Hematopoietic and Immune Cell Fate: Implications for Osteoporosis Therapies.

Authors:  Betsabel Chicana; Cristine Donham; Alberto J Millan; Jennifer O Manilay
Journal:  Curr Osteoporos Rep       Date:  2019-04       Impact factor: 5.096

3.  Intron retention is a widespread mechanism of tumor-suppressor inactivation.

Authors:  Hyunchul Jung; Donghoon Lee; Jongkeun Lee; Donghyun Park; Yeon Jeong Kim; Woong-Yang Park; Dongwan Hong; Peter J Park; Eunjung Lee
Journal:  Nat Genet       Date:  2015-10-05       Impact factor: 38.330

4.  Repurposing propranolol as an antitumor agent in von Hippel-Lindau disease.

Authors:  Matthew J Shepard; Alejandro Bugarini; Nancy A Edwards; Jie Lu; Qi Zhang; Tianxia Wu; Zhengping Zhuang; Prashant Chittiboina
Journal:  J Neurosurg       Date:  2018-10-01       Impact factor: 5.115

5.  Epidemiological study of a von Hippel-Lindau family in northwest China.

Authors:  Jingyao Zhang; Dapeng Wu; Hong Ai; Jigang Bai; Shunbin Dong; Qinling Yang; Kai Qu; Lei Zhou; Xinsen Xu; Chang Liu
Journal:  Front Med       Date:  2013-07-05       Impact factor: 4.592

6.  Transdermal deferoxamine prevents pressure-induced diabetic ulcers.

Authors:  Dominik Duscher; Evgenios Neofytou; Victor W Wong; Zeshaan N Maan; Robert C Rennert; Mohammed Inayathullah; Michael Januszyk; Melanie Rodrigues; Andrey V Malkovskiy; Arnetha J Whitmore; Graham G Walmsley; Michael G Galvez; Alexander J Whittam; Michael Brownlee; Jayakumar Rajadas; Geoffrey C Gurtner
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-22       Impact factor: 11.205

Review 7.  Recent advances in intradural spinal tumors.

Authors:  Muhammad M Abd-El-Barr; Kevin T Huang; Ziev B Moses; J Bryan Iorgulescu; John H Chi
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

8.  Novel homozygous VHL mutation in exon 2 is associated with congenital polycythemia but not with cancer.

Authors:  Lucie Lanikova; Felipe Lorenzo; Chunzhang Yang; Hari Vankayalapati; Richard Drachtman; Vladimir Divoky; Josef T Prchal
Journal:  Blood       Date:  2013-03-28       Impact factor: 22.113

Review 9.  Spinal cord tumours: advances in genetics and their implications for treatment.

Authors:  Patricia L Zadnik; Ziya L Gokaslan; Peter C Burger; Chetan Bettegowda
Journal:  Nat Rev Neurol       Date:  2013-03-26       Impact factor: 42.937

Review 10.  Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.

Authors:  Nicole Rainville; Edward Jachimowicz; Don M Wojchowski
Journal:  Expert Opin Ther Targets       Date:  2015-09-30       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.